Apogee Therapeutics, Inc.

Overview

• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersSan Francisco, California¹
• Business address1 Letterman Drive, Building B, San Francisco, Ca³
• Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (“I&I”) markets, including for the treatment of atopic dermatitis (“AD”), asthma, eosinophilic esophagitis (“EoE”), chronic obstructive pulmonary disease (“COPD”), and other I&I indications. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties.⁴ From its latest annual report

Corporate structure

Apogee Therapeutics, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Apogee Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We maintain a corporate headquarters in Waltham, Massachusetts, laboratory and office space in Boston, Massachusetts, office space in San Francisco, California and otherwise operate virtually in the United States. Our corporate headquarters in Waltham, Massachusetts, consists of 1,087 square feet of leased office space under a lease agreement that expires in September 2026. We also lease a laboratory facility located in Boston, Massachusetts, which consists of 17,685 square feet of R&D laboratories and office space under a lease agreement that expires in November 2026, with the option to extend for one year. In September 2024, the Company entered into a lease agreement for 15,710 square feet of office space in San Francisco, California. The lease expires in September 2029 with two one-year options to extend. We believe these arrangements support our current needs. If we require additional space, we believe that we will be able to obtain such space on acceptable, commercially reasonable terms.

Item 2 of the 10-K filed Mar 2, 2026.⁴

Leadership

Who has led Apogee Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMichael Thomas Henderson Jul 13, 2023 to now¹¹
• Chief financial officerJane Henderson Jul 13, 2023 to now¹²

Former names

• Apogee Therapeutics, LLCApr 28, 2023 to Jun 12, 2023³

Timeline

1. Sep 3, 20268-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer²¹
2. Aug 11, 20268-K Executive or director change; Shareholder vote²²
3. Aug 10, 20268-K Results of operations²³
4. Jun 22, 20268-K Entered a material agreement²⁴
5. Jun 22, 20268-K Entered a material agreement; Shareholder vote; Regulation FD disclosure²⁵
6. Jun 12, 20268-K Shareholder vote²⁶
7. May 27, 20268-K Regulation FD disclosure; Other events²⁷
8. May 27, 20268-K Entered a material agreement; Regulation FD disclosure²⁸
9. May 11, 20268-K Results of operations²⁹
10. Apr 24, 20268-K Executive or director change³⁰
11. Mar 25, 20268-K Entered a material agreement³¹
12. Mar 23, 20268-K Regulation FD disclosure; Other events³²
13. Jul 13, 2023New chief executive Michael Thomas Henderson becomes CEO¹¹

Calendar

Coming up

1. Around Nov 9, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

1. Aug 10, 2026Reported quarterly or annual results²³
2. May 11, 2026Reported quarterly or annual results²⁹
3. Nov 10, 2025Reported quarterly or annual results³³
4. Aug 11, 2025Reported quarterly or annual results³⁴
5. May 12, 2025Reported quarterly or annual results³⁵
6. Mar 3, 2025Reported quarterly or annual results³⁶
7. Nov 12, 2024Reported quarterly or annual results³⁷
8. Aug 12, 2024Reported quarterly or annual results³⁸

Drug trials and FDA: coming up

1. Nov 2026Phase 2 trial readout expected Phase 2 trial of APG777 in Atopic Dermatitis: primary completion expected Nov 2026 (ClinicalTrials.gov NCT06395948).³⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

316 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 40 major events, 128 insider forms, 40 large holders, 95 other. The latest 20:

1. Sep 14, 202615-12G EDGAR
2. Sep 8, 2026SCHEDULE 13D/A EDGAR
3. Sep 3, 20264 EDGAR
4. Sep 3, 20264 EDGAR
5. Sep 3, 20264 EDGAR
6. Sep 3, 20264 EDGAR
7. Sep 3, 20264 EDGAR
8. Sep 3, 20264 EDGAR
9. Sep 3, 20264 EDGAR
10. Sep 3, 20264 EDGAR
11. Sep 3, 2026POSASR EDGAR
12. Sep 3, 2026S-8 POS EDGAR
13. Sep 3, 2026S-8 POS EDGAR
14. Sep 3, 2026S-8 POS EDGAR
15. Sep 3, 2026S-8 POS EDGAR
16. Sep 3, 2026S-8 POS EDGAR
17. Sep 3, 20268-K EDGAR
18. Sep 3, 2026SCHEDULE 13D/A EDGAR
19. Sep 3, 20264 OWNERSHIP DOCUMENT EDGAR
20. Aug 11, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

66 open-market trades by officers, directors and large owners since October 2021: 3 buys and 63 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Venrock Healthcare Capital Partners III, L.P.SCHEDULE 13D/A, 2 filings Jul 28, 2023 to Sep 8, 2026⁴⁰
• Fairmount Funds Management LLCSCHEDULE 13D/A, 8 filings Jul 21, 2023 to Sep 3, 2026⁴¹
• FMR LLCSCHEDULE 13G/A, 5 filings Aug 10, 2023 to Jul 8, 2026⁴²
• T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A, 3 filings Mar 6, 2026 to Jul 8, 2026⁴³
• Wellington Management CompanySCHEDULE 13G/A, 6 filings Oct 4, 2024 to Jul 8, 2026⁴⁴
• VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Jan 30, 2026 to Mar 26, 2026⁴⁵
• RTW INVESTMENTS, LPSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Feb 17, 2026⁴⁶
• DRIEHAUS CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Nov 14, 2025⁴⁷
• BlackRockSCHEDULE 13G/A, 3 filings Oct 22, 2024 to Jul 16, 2025⁴⁸
• Deep Track Capital, LPSC 13G/A, 3 filings Jul 24, 2023 to Nov 14, 2024⁴⁹
• RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 2024⁵⁰
• ACCESS INDUSTRIES MANAGEMENT, LLCSC 13G/A, 2 filings Nov 3, 2023 to Nov 4, 2024⁵¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Apogee Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARApogee Therapeutics, Inc.¹
• CIK0001974640
• Employer ID (EIN)93-4958665⁴
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address1 Letterman Drive, Building B, San Francisco, CA¹
• Phone650-394-5230¹
• Shares outstanding55,998,605 Voting Common Stock shares; 13,486,642 Nonvoting Common Stock shares as of Feb 23, 2026⁴
• Public float$1.8B as of Jun 30, 2025⁴
• AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceApr 28, 2023¹
• Filings318 in all: 4 (113), 8-K (40), 144 (34), SCHEDULE 13G/A (13), 10-Q (10), 3 (10), DEFA14A (9), SC 13G (8)¹
  All 39 form types

  CORRESP (6), SC 13G/A (6), SCHEDULE 13D/A (6), 3/A (5), S-8 (5), S-8 POS (5), 424B5 (4), UPLOAD (4), 10-K (3), ARS (3), DEF 14A (3), SCHEDULE 13G (3), 424B4 (2), DRS (2), EFFECT (2), S-1 (2), S-1/A (2), S-1MEF (2), SC 13D (2), SC 13D/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS/A (1), DRSLTR (1), POSASR (1), PREM14A (1), S-3ASR (1)

• Latest filingsAnnual report (10-K) Mar 2, 2026
  Quarterly report (10-Q) Aug 10, 2026
  Proxy statement (DEF 14A) Apr 24, 2026
  Latest 8-K (8-K) Sep 3, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 2, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Apogee Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 2, 2026: 69 risks under these headings, as written.⁴

• We are a clinical stage biotechnology company with a limited operating history, we are currently conducting clinical trials, and we have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.
• We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts.
• We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products approved for sale, have not generated any revenue from our programs and may never generate revenue or become profitable.
• We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates.
• Our programs are in clinical and preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our current or future collaborators are unable to complete development of, or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.
• We are substantially dependent on the success of our product candidates, zumilokibart, APG279, APG273, APG990, APG333 and APG808 and our ongoing and anticipated trials may not be successful.
• If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our stock price may decline.
• Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of product candidates with commercial value.
• Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our programs, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such program.
• We anticipate developing certain product candidates for use in combination with one or more of our other product candidates, and regulatory or safety issues with combination therapies may delay or prevent development and approval of our product candidates.
• If we encounter difficulties enrolling patients in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• Preliminary, “topline” or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures.

Legal proceedings

We are not party to any material legal proceedings at this time. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.⁴